Kura Oncology, Inc. (KURA)
13.11
+0.22
(+1.71%)
USD |
NASDAQ |
Sep 02, 16:00
13.22
+0.11
(+0.84%)
Pre-Market: 08:13
Kura Oncology Research and Development Expense (TTM) : 259.47M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 259.47M |
| March 31, 2026 | 260.36M |
| December 31, 2025 | 251.07M |
| September 30, 2025 | 238.93M |
| June 30, 2025 | 212.73M |
| March 31, 2025 | 189.67M |
| December 31, 2024 | 169.97M |
| September 30, 2024 | 150.23M |
| June 30, 2024 | 137.86M |
| March 31, 2024 | 126.31M |
| December 31, 2023 | 115.24M |
| September 30, 2023 | 105.37M |
| June 30, 2023 | 101.02M |
| March 31, 2023 | 97.09M |
| December 31, 2022 | 92.81M |
| September 30, 2022 | 91.10M |
| June 30, 2022 | 88.49M |
| March 31, 2022 | 85.31M |
| December 31, 2021 | 84.72M |
| September 30, 2021 | 81.29M |
| June 30, 2021 | 75.52M |
| March 31, 2021 | 68.15M |
| Date | Value |
|---|---|
| December 31, 2020 | 60.40M |
| September 30, 2020 | 56.34M |
| June 30, 2020 | 52.28M |
| March 31, 2020 | 50.02M |
| December 31, 2019 | 47.83M |
| September 30, 2019 | 46.45M |
| June 30, 2019 | 45.57M |
| March 31, 2019 | 45.60M |
| December 31, 2018 | 46.79M |
| September 30, 2018 | 42.82M |
| June 30, 2018 | 38.30M |
| March 31, 2018 | 32.48M |
| December 31, 2017 | 26.43M |
| September 30, 2017 | 23.81M |
| June 30, 2017 | 21.98M |
| March 31, 2017 | 21.27M |
| December 31, 2016 | 20.40M |
| September 30, 2016 | 20.01M |
| June 30, 2016 | 19.37M |
| March 31, 2016 | 18.63M |
| December 31, 2015 | 17.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | 47.16M |
| Fortress Biotech, Inc. | 1.186M |
| Syndax Pharmaceuticals, Inc. | 261.79M |
| Spero Therapeutics, Inc. | 20.53M |
| Gossamer Bio, Inc. | 163.94M |